Integrated Genomic Analysis of Pancreatic Ductal Adenocarcinomas Reveals Genomic Rearrangement Events as Significant Drivers of Disease.

Many somatic mutations have been detected in pancreatic ductal adenocarcinoma (PDAC), leading to the identification of some key drivers of disease progression, but the involvement of large genomic rearrangements has often been overlooked. In this study, we performed mate pair sequencing (MPseq) on genomic DNA from 24 PDAC tumors, including 15 laser-captured microdissected PDAC and 9 patient-derived xenografts, to identify genome-wide rearrangements. Large genomic rearrangements with intragenic breakpoints altering key regulatory genes involved in PDAC progression were detected in all tumors. SMAD4, ZNF521, and FHIT were among the most frequently hit genes. Conversely, commonly reported genes with copy number gains, including MYC and GATA6, were frequently observed in the absence of direct intragenic breakpoints, suggesting a requirement for sustaining oncogenic function during PDAC progression. Integration of data from MPseq, exome sequencing, and transcriptome analysis of primary PDAC cases identified limited overlap in genes affected by both rearrangements and point mutations. However, significant overlap was observed in major PDAC-associated signaling pathways, with all PDAC exhibiting reduced SMAD4 expression, reduced SMAD-dependent TGFβ signaling, and increased WNT and Hedgehog signaling. The frequent loss of SMAD4 and FHIT due to genomic rearrangements strongly implicates these genes as key drivers of PDAC, thus highlighting the strengths of an integrated genomic and transcriptomic approach for identifying mechanisms underlying disease initiation and progression.

[1]  Zhen Liu,et al.  Fragile Histidine Triad (FHIT) Suppresses Proliferation and Promotes Apoptosis in Cholangiocarcinoma Cells by Blocking PI3K-Akt Pathway , 2014, TheScientificWorldJournal.

[2]  Manuel Hidalgo,et al.  Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer , 2011, Proceedings of the National Academy of Sciences.

[3]  Joel H. Saltz,et al.  BMC Systems Biology , 2022 .

[4]  K. Cengel Targeting Sonic Hedgehog: A New Way to Mow Down Pancreatic Cancer? , 2004, Cancer biology & therapy.

[5]  R. Gibbs,et al.  Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. , 2013, Gastroenterology.

[6]  D. Stover,et al.  Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics. , 2013, Neoplasia.

[7]  Huamin Wang,et al.  Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype , 2015, Laboratory Investigation.

[8]  C. Daniels,et al.  Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. , 2004, The Journal of clinical investigation.

[9]  I. Schmidt-Wolf,et al.  Effect of Wnt inhibitors in pancreatic cancer. , 2014, Anticancer research.

[10]  Sarah H. Johnson,et al.  Genomic rearrangements define lineage relationships between adjacent lepidic and invasive components in lung adenocarcinoma. , 2014, Cancer research.

[11]  J. Jeekel,et al.  Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? , 2005, Langenbeck's Archives of Surgery.

[12]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[13]  A. Viale,et al.  Genome-wide analysis of the role of copy-number variation in pancreatic cancer risk , 2013, Front. Genet..

[14]  K. Shigemoto,et al.  The Role of Zinc Finger Protein 521/Early Hematopoietic Zinc Finger Protein in Erythroid Cell Differentiation* , 2009, Journal of Biological Chemistry.

[15]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[16]  T. Fitzgerald,et al.  Changing Incidence of Pancreatic Neoplasms: A 16-Year Review of Statewide Tumor Registry , 2008, Pancreas.

[17]  D Saur,et al.  Oncogenic KRAS signalling in pancreatic cancer , 2014, British Journal of Cancer.

[18]  K. Creek,et al.  Six1 promotes epithelial-mesenchymal transition and malignant conversion in human papillomavirus type 16-immortalized human keratinocytes. , 2014, Carcinogenesis.

[19]  R. Fodde,et al.  Smad4 haploinsufficiency in mouse models for intestinal cancer , 2006, Oncogene.

[20]  Travis M. Drucker,et al.  Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Murphy,et al.  Cell-Type-Specific Activation of PAK2 by Transforming Growth Factor β Independent of Smad2 and Smad3 , 2003, Molecular and Cellular Biology.

[22]  Travis M. Drucker,et al.  BIMA V3: an aligner customized for mate pair library sequencing , 2014, Bioinform..

[23]  Zhaoming Li,et al.  Six1 Promotes Proliferation of Pancreatic Cancer Cells via Upregulation of Cyclin D1 Expression , 2013, PloS one.

[24]  R. Hruban,et al.  Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. , 2007, Cancer cell.

[25]  Hui Wang,et al.  Decreased fragile histidine triad expression in colorectal cancer and its association with apoptosis inhibition. , 2007, World journal of gastroenterology.

[26]  Lijuan Lin,et al.  Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma. , 2014, Experimental and molecular pathology.

[27]  S. Malkoski,et al.  Two sides of the story? Smad4 loss in pancreatic cancer versus head‐and‐neck cancer , 2012, FEBS letters.

[28]  D. Birnbaum,et al.  Genome profiling of pancreatic adenocarcinoma , 2011, Genes, chromosomes & cancer.

[29]  N. Heerema,et al.  Characterization of the role of Fhit in suppression of DNA damage. , 2013, Advances in biological regulation.

[30]  C. Croce,et al.  Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer. , 2003, Cancer research.

[31]  Rodney J Scott,et al.  Smad4 haploinsufficiency: a matter of dosage , 2008, PathoGenetics.

[32]  V. Velculescu,et al.  Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors , 2012, Clinical Cancer Research.

[33]  Winnie S. Liang,et al.  Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing , 2012, PloS one.

[34]  Damian Szklarczyk,et al.  STRING v9.1: protein-protein interaction networks, with increased coverage and integration , 2012, Nucleic Acids Res..

[35]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[36]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[37]  C. Hui,et al.  Sonic hedgehog-dependent activation of Gli2 is essential for embryonic hair follicle development. , 2003, Genes & development.

[38]  R. Schmid,et al.  Genetic alterations in pancreatic carcinoma , 2003, Molecular Cancer.

[39]  B. Pützer,et al.  Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction. , 2001, Cancer research.

[40]  M. Resh,et al.  Hedgehog acyltransferase as a target in pancreatic ductal adenocarcinoma , 2014, Oncogene.

[41]  Michael A. Choti,et al.  Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets , 2015, Nature Communications.

[42]  M. van de Rijn,et al.  Genomic Profiling Identifies GATA6 as a Candidate Oncogene Amplified in Pancreatobiliary Cancer , 2008, PLoS genetics.

[43]  C. Croce,et al.  Coordinate Loss of Fragile Gene Expression in Pancreatobiliary Cancers: Correlations Among Markers and Clinical Features , 2009, Annals of Surgical Oncology.

[44]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[45]  Sarah H. Johnson,et al.  Mate Pair Sequencing of Whole-Genome-Amplified DNA Following Laser Capture Microdissection of Prostate Cancer , 2012, DNA research : an international journal for rapid publication of reports on genes and genomes.

[46]  H. Moch,et al.  Molecular foundations for personalized therapy in prostate cancer. , 2015, Current drug targets.

[47]  D. Birnbaum,et al.  The emerging role of the TGFβ tumor suppressor pathway in pancreatic cancer , 2012, Cell cycle.

[48]  Wei He,et al.  A FoxO–Smad synexpression group in human keratinocytes , 2006, Proceedings of the National Academy of Sciences.

[49]  D. Birnbaum,et al.  Chromosome arm 8p and cancer: a fragile hypothesis. , 2003, The Lancet. Oncology.

[50]  R. McWilliams,et al.  Aberrant signaling pathways in pancreatic cancer: A two compartment view , 2012, Molecular carcinogenesis.